Brief: Pharmacyte Biotech Issues Response To Iroquois Capital Letter
08/06/2022 13:38
June 8 (Reuters) - PharmaCyte Biotech Inc PMCB.O :
* PHARMACYTE BIOTECH ISSUES RESPONSE TO IROQUOIS CAPITAL
LETTER
AND ANNOUNCES ADDITIONAL STEPS TO INCREASE SHAREHOLDER VALUE
* PHARMACYTE BIOTECH INC - "AGREE WITH OUR SHAREHOLDERS THAT
OUR
SHARES ARE SIGNIFICANTLY UNDERVALUED"
* PHARMACYTE BIOTECH INC - LAST WEEK AUTHORIZED A SHARE
REPURCHASE
PROGRAM TO PURCHASE UP TO $10 MILLION OF OUR COMMON STOCK OVER A
TWO-YEAR PERIOD
* PHARMACYTE BIOTECH INC - "VALUE COMMUNICATION WITH OUR
SHAREHOLDERS AND WILL INSTITUTE QUARTERLY CONFERENCE CALLS"
Source text for Eikon: ID:nBw4PjYnza
Further company coverage: PMCB.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Pharmacyte Biotech
See all newsBrief: Pharmacyte Biotech Inc - Increases Stake In Tnf Pharmaceuticals By $3 Million
Brief: PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
Brief: Pharmacyte Biotech Acquires $5 Million Stake In Emerging Women’S Health Innovator Femasys
Brief: Femasys Inc. Secures Additional Financing With Strategic Investment From Investors Led By Pharmacyte Biotech
Brief: Pharmacyte Biotech Announces Final Results Of Tender Offer